Table 1.

The effect of the various inhibitors tested on [Ca^2 +]_o-induced vasorelaxations.

	EC50 (mM)	Emax (%)	n
Controls	2.2 ± 0.04	96 ± 3.4	8
-Endothelium	−	−	8
+ Calhex-231 (μM)	4 ± 0.51⁎⁎⁎⁎	54.6 ± 4.6⁎⁎	4
+ L-NAME (300 μM)	4.1 ± 0.01⁎⁎⁎⁎	8.3 ± 11⁎⁎⁎⁎	7
+ ODQ (10 μM)	3.1. ± 0.59⁎⁎⁎	30.8 ± 14⁎⁎⁎	4
+ KT5283 (1 μM)	4.5 ± 0.42⁎⁎⁎	53.4 ± 12⁎⁎	4
+ IbTx (100 nM)	4.3 ± 0.21⁎⁎⁎⁎	51.9 ± 5.1⁎⁎⁎	4
+ IbTx (100 nM) + CbTx (100 nM)	5.1 ± 0.03⁎⁎⁎⁎	15 ± 11.7⁎⁎⁎⁎	5
+ IbTX (200 nM)	4.1 ± 0.34⁎⁎⁎⁎	45 ± 7.2⁎⁎⁎	5
+ Apamin (100 nM)	2.1 ± 0.01	93 ± 3.3	4
+ Linopirdine (10 μM)	2.1 ± 0.22	72 ± 3.3⁎⁎	4
+ Indomethacin(10 μM)	2.3 ± 0.05	92 ± 3.5	5
+ Glibenclamide	2.1 ± 0.31	91 ± 4.6	4
+ L-NAME (300 μM) + CbTx(100 nM)	−	−	5

EC₅₀ and E_max values were compared with Student's t-test vs. corresponding controls. n = animals used, with at least 3 vessel segments per animal.

^⁎⁎p < 0.01.

^⁎⁎⁎p < 0.001.

^⁎⁎⁎⁎p < 0.0001.